SM
PMCB icon

Sabby Management’s PharmaCyte Biotech PMCB Stock Holding History

Sabby Management’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-102
Closed -$23K – 134
2022
Q2 		$23K Buy
+102
New +$223 0.02% 116
2022
Q1 		– Sell
-431
Closed -$108K – 183
2021
Q4 		$108K Buy
+431
New +$1.19K 0.02% 153

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Sabby Management's PMCB Position: Q1 2026 in Review

Sabby Management sold out of PharmaCyte Biotech (PMCB) in Q1 2026, closing a stake of 100,000 shares — an estimated $72.4K sold.

Sabby Management first reported a position in PMCB in Q3 2021 and held it in 9 quarters. The position peaked at $3.2M in Q3 2021. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Sabby Management reported no remaining PharmaCyte Biotech position as of Q1 2026 after selling out during the quarter.
  • Sabby Management sold 100,000 PharmaCyte Biotech shares in Q1 2026, an estimated $72.4K.
  • Sabby Management first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 9 quarters.
  • Sabby Management's PharmaCyte Biotech position peaked at $3.2M in Q3 2021.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Sabby Management's 13F filing for Q1 2026, filed 15 May 2026.